SCR-1481B1 (also known as c-Met inhibitor 2) is a novel potent and selective MET inhibitor. SCR-1481B1 inhibited MET kinase with IC50 value of 1.7 nM. It has potential anticancer activities. With an IC50 value of 1.7 nM, SCR-1481B1 inhibited MET kinase. It may possess anticancer properties. Strong substance SCR-1481B1 functions as a VEGFR inhibitor in addition to its activity against cancers that is reliant on Met activation. 3-amino is the chemical name. 2.-hydroxyethyl-3-pentane 1-(5,5-diol) (3-((4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)carbamoyl)-5-(4-fluorophenyl) 1-oxopyridin-1(4H)-yl)methyl phosphate.
Physicochemical Properties
| Molecular Formula | C28H29CLF2N5O10P |
| Molecular Weight | 699.980933904648 |
| Exact Mass | 699.13 |
| Elemental Analysis | C, 50.18; H, 4.75; Cl, 4.78; F, 5.12; N, 9.44; O, 21.56; P, 4.17 |
| CAS # | 1174161-86-4 |
| Related CAS # | 1174161-86-4 (tris);1174161-69-3; |
| PubChem CID | 119081412 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 47 |
| Complexity | 1080 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | SDCKZXWUASKHNF-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C24H18ClF2N4O7P.C4H11NO3/c25-21-20(7-8-29-23(21)28)38-19-6-5-15(9-18(19)27)30-24(33)17-11-31(12-37-39(34,35)36)10-16(22(17)32)13-1-3-14(26)4-2-13;5-4(1-6,2-7)3-8/h1-11H,12H2,(H2,28,29)(H,30,33)(H2,34,35,36);6-8H,1-3,5H2 |
| Chemical Name | [3-[[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]carbamoyl]-5-(4-fluorophenyl)-4-oxopyridin-1-yl]methyl dihydrogen phosphate;2-amino-2-(hydroxymethyl)propane-1,3-diol |
| Synonyms | BMS-817378; BMS 817378; BMS817378; SCR-1481B1; SCR 1481B1; SCR1481B1 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | VEGFR1 | ||
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay | BMS-794833, the active component of BMS-817378, has an IC50 of 1.7 nM/15 nM, making it a strong ATP competitive inhibitor of Met/VEGFR2. It also has an IC50 of <3 nM for Ron, Axl, and Flt3. | ||
| Animal Protocol |
|
||
| References |
[1]. 4-pyridinone compounds and their use for cancer. WO/2009094417/A1. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4286 mL | 7.1431 mL | 14.2861 mL | |
| 5 mM | 0.2857 mL | 1.4286 mL | 2.8572 mL | |
| 10 mM | 0.1429 mL | 0.7143 mL | 1.4286 mL |